Trade Summary

4 days ago, Palleiko Benjamin L, serving as CEO at Kalvista Pharmaceuticals, Inc. (KALV), sold 10,034 shares at $15.57 per share, for a total transaction value of $156,197.00. Following this transaction, Palleiko Benjamin L now holds 442,883 shares of KALV.

This sale represents a 2.00% decrease in Palleiko Benjamin L's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Monday, February 23, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, February 24, 2026, 1 day after the trade was made.

Kalvista Pharmaceuticals, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.